Opinion
Video
Improving Insurance Coverage for RSV Vaccines
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
Video Player is loading.
Video content above is prompted by the following questions:
- With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
- How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
- How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
Related Videos
Navigating Cost Considerations in Treatment Selection of mCRC Agents
Pharmacist-Led Strategies for Adverse Event Management in mCRC
The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
Evolution of Oncology Pharmacy Practice in mCRC
The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management
Optimizing Treatment Sequencing in Advanced Colorectal Cancer
Quality of Life and Patient Outcomes in mCRC Treatment
Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC
Treatment Options in mCRC: A Clinical Overview
Related Content
